Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-383
- Development stage
- Phase 3
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-383 is a fixed-dose combination (FDC) therapy developed by Chong Kun Dang Pharmaceutical for the treatment of type 2 diabetes mellitus. It consists of three active ingredients: lobeglitazone (a PPAR-gamma agonist), empagliflozin (an SGLT2 inhibitor), and metformin (a biguanide). This triple combination aims to improve glycemic control by targeting multiple pathophysiological pathways of diabetes, including insulin resistance, renal glucose reabsorption, and hepatic glucose production. Clinical development has included Phase 1 studies evaluating the pharmacokinetics, safety, and food effects of the combination compared to the co-administration of its individual components.
- Other names
- lobeglitazone + sitagliptin + metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)PPARD (Peroxisome proliferator–activated receptor delta)SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on CKD-383.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-383.